Schizophrenia News and Research

Latest Schizophrenia News and Research

Cardiometabolic risk high for schizophrenia patients

The risk for abdominal obesity may be increased as much as fourfold for patients with multi-episode schizophrenia compared with the rest of the population, reveal findings from a meta-analysis.

17 Oct 2013

Scientists uncover faulty brain mechanism that may underlie schizophrenia in humans

Working with mice genetically engineered to display symptoms of schizophrenia, neuroscientists at the RIKEN-MIT Center for Neural Circuit Genetics at the Picower Institute for Learning and Memory at MIT have uncovered a faulty brain mechanism that may underlie schizophrenia and other psychiatric disorders in humans.

17 Oct 2013

Seven promising scientists named 2013 NYSCF - Robertson Investigators

The New York Stem Cell Foundation today named seven of the most promising scientists as its 2013 NYSCF - Robertson Investigators.

16 Oct 2013

Cash rewards encourage antipsychotic injection adherence

Offering “modest” financial incentives to patients receiving maintenance antipsychotic treatment by depot injection can encourage them to adhere to the regimen, shows a randomized trial.

15 Oct 2013

Kraepelin distinctions back in favor

Modern statistical methods support Kraepelin’s original distinction between schizophrenia and bipolar disorder, but not the more recent schizoaffective disorder category, say researchers.

11 Oct 2013

Researchers identify gene that orchestrates important branching of nerve fibers

Our ability to detect heat, touch, tickling and other sensations depends on our sensory nerves. Now, for the first time, researchers at Albert Einstein College of Medicine of Yeshiva University have identified a gene that orchestrates the crucially important branching of nerve fibers that occurs during development. The findings were published online today in the journal Cell.

11 Oct 2013

Alkermes' ALKS 5461 drug gets FDA Fast Track status for major depressive disorder

Alkermes plc today announced that the U.S. Food and Drug Administration has granted Fast Track status for ALKS 5461 for the adjunctive treatment of major depressive disorder in patients with an inadequate response to standard therapies.

10 Oct 2013

Heptares' StaR platform offers breakthrough solution to challenge associated with antibodies therapeutics

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, achieved the first research milestone in its antibody therapeutics alliance with MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX), announced in February 2013.

10 Oct 2013

Lundbeck, Otsuka to continue development of Lu AE58054 compound for Alzheimer's disease

H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. announced today the continuation of the development program of Lu AE58054 for the treatment of Alzheimer's disease, initiating the first out of four phase III clinical trials with the compound.

10 Oct 2013

Alkermes announces plans to advance ALKS 5461 phase 3 program for major depressive disorder

Alkermes plc today announced that it has successfully completed its End-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA), and the company plans to advance ALKS 5461 into phase 3 development in early 2014.

9 Oct 2013

UCLA investigates high rates of schizophrenia in people with 22q11.2 deletion syndrome

UCLA has joined an international consortium to investigate the high rates of schizophrenia and other neuropsychiatric disorders in those who are affected with Chromosome 22q11.2 deletion syndrome, a disorder caused by the deletion of a small piece of chromosome number 22.

9 Oct 2013

Researchers study link between newborn infections and later behavior problems

Researchers exploring the link between newborn infections and later behavior and movement problems have found that inflammation in the brain keeps cells from accessing iron that they need to perform a critical role in brain development.

9 Oct 2013

Alkermes completes patient enrollment in phase 3 study of aripiprazole lauroxil in schizophrenia patients

Alkermes plc (NASDAQ: ALKS) today announced completion of patient enrollment in the pivotal, multinational phase 3 study evaluating aripiprazole lauroxil in patients with schizophrenia.

9 Oct 2013

‘Targeted’ motivational interviewing may improve antipsychotic adherence

Motivational interviewing may help specific subgroups of patients with schizophrenia to adhere to their antipsychotic medication, a study suggests.

8 Oct 2013

Brain & Behavior Research Foundation to hold research symposium on mental health

The Brain & Behavior Research Foundation, an organization dedicated to improving the lives of those with mental illness through the transformative power of neuroscience and psychiatric research, will hold its 25th Annual Mental Health Research Symposium on Friday, October 25th from 9:00 am to 4:30 p.m. at the Kaufman Music Center, located at 129 W. 67th St. in New York City.

8 Oct 2013

NAC amino acid may offer new treatment options for psychiatric disorders

Improved understanding of the roles of inflammation and oxidative stress in psychiatric disorders has generated new leads in the search for novel therapies. One such investigative compound currently in clinical trials is an amino acid, N-Acetyl Cysteine (NAC), which appears to reduce the core symptoms of bipolar disorder, schizophrenia, depression, autism and cravings in addictions including cocaine, cannabis abuse and cigarette smoking.

8 Oct 2013

Brain & Behavior Research Foundation to honor 7 scientists for exceptional research on mental health

The Brain & Behavior Research Foundation celebrates the transformative power of neuroscience and psychiatric research to improve the lives of those with mental illness. Seven exceptional scientists will be honored at the Annual National Awards Dinner at the Pierre Hotel in New York City on Friday, October 25, 2013.

7 Oct 2013

Penn Medicine receives $12M NIHM grant for genetics study that points causes of mental illness

A major international consortium co-led by Penn Medicine has received a $12 million National Institute of Mental Health (NIHM) grant for a large-scale genetics study investigating why patients with chromosome 22q11.2 deletion syndrome have an increased risk of schizophrenia and other psychiatric disorders.

4 Oct 2013

CHOP’s 22q and You Center plays major role in brain and behavior consortium

Genetics experts from The Children's Hospital of Philadelphia (CHOP) are among the top leaders of a major international collaboration researching why patients with chromosome 22q11.2 deletion syndrome have an elevated risk of schizophrenia and other psychiatric illnesses.

4 Oct 2013

Parkinsonism predicts schizophrenia cognitive course

Parkinsonism is common in patients with first-episode psychosis and is predictive of cognitive impairment, say researchers.

3 Oct 2013

Schizophrenia News and Research

Latest Schizophrenia News and Research

Cardiometabolic risk high for schizophrenia patients

Scientists uncover faulty brain mechanism that may underlie schizophrenia in humans

Seven promising scientists named 2013 NYSCF - Robertson Investigators

Cash rewards encourage antipsychotic injection adherence

Kraepelin distinctions back in favor

Researchers identify gene that orchestrates important branching of nerve fibers

Alkermes' ALKS 5461 drug gets FDA Fast Track status for major depressive disorder

Heptares' StaR platform offers breakthrough solution to challenge associated with antibodies therapeutics

Lundbeck, Otsuka to continue development of Lu AE58054 compound for Alzheimer's disease

Alkermes announces plans to advance ALKS 5461 phase 3 program for major depressive disorder

UCLA investigates high rates of schizophrenia in people with 22q11.2 deletion syndrome

Researchers study link between newborn infections and later behavior problems

Alkermes completes patient enrollment in phase 3 study of aripiprazole lauroxil in schizophrenia patients

‘Targeted’ motivational interviewing may improve antipsychotic adherence

Brain & Behavior Research Foundation to hold research symposium on mental health

NAC amino acid may offer new treatment options for psychiatric disorders

Brain & Behavior Research Foundation to honor 7 scientists for exceptional research on mental health

Penn Medicine receives $12M NIHM grant for genetics study that points causes of mental illness

CHOP’s 22q and You Center plays major role in brain and behavior consortium

Parkinsonism predicts schizophrenia cognitive course

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Schizophrenia News and Research

Latest Schizophrenia News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in